Compare Essex Property Trust, Inc. (ESS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs TG Therapeutics Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Essex Property Trust, Inc. is far larger — about 2.4× TG Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ESS | TGTX | |
|---|---|---|
Market Cap | $18.15B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $59.06 |
52-Week Low | $239.61 | $26.94 |
Enterprise Value | $24.75B | $7.84B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $281.27, down 0.69% on the day, with a bearish technical signal. The company reported a Q2 2026 EPS miss ($0.97 vs. $1.46 expected) but raised full-year FFO guidance. Revenue grew to $1.89B in 2025, with a strong net income margin of 35.48%, though profitability is projected to moderate in 2026. The stock is supported by a $2.59 dividend and a consensus price target of $305.86, implying potential upside.
The outlook is mixed: raised guidance and institutional buying signal confidence, but technical weakness and a high debt load pose risks. The stock offers income and growth potential if operational execution improves, yet faces headwinds from regional market softness and interest rate sensitivity.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
